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Abstract 
Objective: To study the association of vaspin with glucose metabolism. 
Design: Cross-sectional and intervention study. 
Subjects and methods: The association of serum vaspin with metabolic and anthropometric 
characteristics was investigated in 108 volunteers. Euglycemic-hyperinsulinemic clamps 
(EHC) were performed in 83 of the participants. Changes of circulating vaspin levels were 
additionally studied in a cross-over study using 300-min EHC with lipid vs saline infusion (n 
= 10). 
Results: Neither glucose tolerance status nor insulin sensitivity, both as measured using EHCs 
and using homeostasis-model-assessment for insulin resistance (HOMA-IR), were 
significantly associated with serum vaspin in the cross-sectional study. Further, there was no 
effect of short-term lipid induced insulin resistance due to a 300 min intravenous lipid 
challenge on circulating vaspin. However, circulating vaspin levels were significantly 
elevated in women using oral contraceptives (OC), both compared to women without OC 
intake (1.17 ± 0.26 vs 0.52 ± 0.09 ng/ml, P = 0.02) and males (1.17 ± 0.26 vs 0.29 ± 0.04 
ng/ml, P = 0.01). After exclusion of OC using females and stratification according to body 
mass index (BMI), a significant sexual dimorphism in subjects with a BMI < 25 kg/m
2 
was 
observed (males 0.21 ± 0.04 ng/ml vs females 0.70 ± 0.16 ng/ml, P = 0.009). 
Conclusion: Our results support the existence of a sexual dimorphism regarding circulating 
vaspin. The lack of an association of serum vaspin with HOMA-IR and M-value indicates, 
however, no major role for vaspin concerning insulin sensitivity in non-diabetic humans. 
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Introduction 
Adipose tissue, recognized today as an active secretory organ, modifies the metabolic state of 
insulin-dependent tissues (1). The protease inhibitor vaspin is a member of the superfamily of 
serpins and was isolated from white adipose tissue (WAT) of Otsuka Long-Evans Tokushima 
fatty (OLETF) rats (2) and humans (3). Observations in animals suggest vaspin to exert 
insulin sensitizing effects mainly targeted on WAT, and diabetic treatment to increase mRNA 
expression and serum levels of vaspin (4). Therefore it has been proposed that the up-
regulation of vaspin represents a compensatory mechanism against rising insulin resistance 
(4,5). Improved insulin sensitivity and altered gene expression of insulin resistance candidate 
genes after administration of recombinant vaspin to a mouse model of diet-induced obesity 
provide support for this hypothesis (2,5). 
In humans with normal glucose metabolism (NGM), serum vaspin has been reported to be 
significantly negatively associated with the body mass index (BMI)-adjusted glucose infusion 
rate (GIR) during steady state of a euglycemic hyperinsulinemic clamp (EHC), and after four 
weeks of physical training the change in serum vaspin correlates positively with the change in 
GIR in a sample of 60 volunteers (6). Further, significant associations between circulating 
vaspin and estimates of insulin resistance such as homeostasis-model-assessment (HOMA-IR) 
were reported. One study supports i.e. a negative correlation between circulating vaspin and 
HOMA-IR (7), while the change in HOMA-IR after weight loss was positively associated 
with altered serum vaspin levels (8,9). Moreover, circulating vaspin shows significant 
associations with several anthropometric and metabolic markers (6,7,8,9,10,11). Additionally, 
the results of a cross-sectional study suggest the existence of a sexual dimorphism, with 
higher circulating vaspin levels in women vs men (10). Yet, this gender difference might be 
influenced by glycemic control (6) or further factors, given that other recent studies showed 
conflicting results (9,11). In concert with the fact that vaspin is mainly expressed in visceral 
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adipose tissue (VAT) (3), current knowledge suggests that serum levels differ depending on 
sex, BMI, metabolic control and fat mass. 
Since in humans modulating factors leading to changes in circulating vaspin are largely 
unknown, we studied associations of serum vaspin with anthropometric and metabolic 
characteristics in a sample of 108 male and female volunteers with a wide range of BMI, age, 
and metabolic control. Further, we analysed the association of serum vaspin with peripheral 
insulin sensitivity measured by EHC in a subset of 83 volunteers. Moreover, it is unknown 
whether the regulation of circulating vaspin in humans is mediated by altered insulin 
resistance or by associated changes in glycemic control. Lipid infusion is recognized to 
acutely produce peripheral insulin resistance within a range of about 200 minutes (12). Thus, 
we further hypothesised that a short-term lipid challenge using conditions known to 
significantly produce peripheral insulin resistance (13) could impact serum vaspin. 
 
Subjects and Methods 
 
Subjects 
The experimental protocol was approved by the local Ethics Committee. All participants gave 
written informed consent before starting the study. 
Cross-sectional study: One-hundred-and-eight male and female participants were included in 
the cross-sectional study. In order to yield stratified groups according to BMI (lean: < 18.5 
kg/m
2
; normal weight: 18.5-24.9 kg/m
2
; overweight: 25.0-29.9 kg/m
2; obese: ≥ 30.0 kg/m2) 
and gender, volunteers were selected as a subset from the cross-sectional Metabolic 
Syndrome Berlin Potsdam (MeSyBePo) study. Details of recruitment were recently published 
(14). All volunteers were screened for serious health problems. Patients with a history of renal 
or hepatic dysfunction, type 2 diabetes, abnormal thyroid function, or glucocorticoid therapy 
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were excluded. A subset of volunteers (n = 83; 40 males; mean age 50.5  1.6 years, mean 
BMI 28.1  0.7 kg/m
2
) additionally underwent EHCs. 
Lipid vs saline intervention study: A further subset of healthy volunteers with NGM was 
enrolled (n = 10; 5 males; mean age 50.6  4.2 years, mean BMI 24.3  1.1 kg/m
2
). Fertile 
female subjects were studied in the early follicular phase of the menstrual cycle. Any renal, 
vascular, or hepatic diseases were exclusion criteria, as well as a history of smoking or any 
diabetes or thyroid medication. 
 
Experimental Design and Assays 
Cross-sectional study: After arrival at the metabolic unit medical history was taken, and the 
subjects underwent physical examination. Fasting venous blood samples were collected and 
stored at -80°C until analysis. Glucose tolerance was tested in all of the subjects by oral 
glucose tolerance tests (OGTT). All the participants of this study had a fasting capillary 
glucose < 5.0 mmol/l and as such normal fasting glucose levels. Participants with NGM were 
defined as having both a normal fasting glucose and a glucose value of < 7.8 mmol/l at the 
120 min OGTT value. Participants with IGT had a normal fasting glucose but a capillary 
glucose at the 120 min OGTT value  7.8 and < 11.1 mmol/l.  
Anthropometric data, as well as arterial blood pressure according to Riva Rocci, were 
obtained as reported previously (14). For the estimation of fasting insulin sensitivity, HOMA-
IR according to the formula [{fasting glucose (mmol/l) × (fasting insulin (pmol/l)/6)}/22.5] 
was applied. EHCs were performed as detailed previously (15, 16). In brief, at –10 min, a 
bolus of insulin was administered over 10 min, adjusted for the body weight of the 
participants, and followed by euglycemic-hyperinsulinemic clamps for at least 2 h, using 40 
mU × m
–2
 × min
–1
 human insulin (Novo Nordisk, Bagsvaard, Denmark) and a variable 
infusion of glucose 20% (Serag Wiessner, Naila, Germany). Arterialized plasma glucose was 
adjusted at 4.4 mmol/l throughout the clamps. Whole-body glucose
 
disposal [expressed as 
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insulin-mediated glucose uptake (M-value)]
 
was calculated from the glucose infusion rate, 
which was constant
 
during the last 30 min of the respective clamps. 
 
Lipid vs saline intervention study: Participants of the lipid vs saline cross-over intervention 
study first underwent EHC until steady state conditions were obtained. Thereafter, EHCs were 
extended for a further 300 min, as detailed recently (16). A constant infusion of a lipid-
solution (Deltalipid LCT 20%; Deltaselect, Pfullingen, Germany; 1.25 ml × min
–1
; contents in 
1.000 ml: soybean oil 200 g, glycerol 25.9 g, egg phospholipids 12 g, oleate 0.3 g; 
supplemented with Heparin-Natrium-25000-ratiopharm; Merckle, Blaubeuren, Germany; 0.4 
IU × kg
–1
 × min
–1
) was added to raise free fatty acid (FFA) concentrations. All participants 
returned to the metabolic unit on a separate day for the control experiments (washout 279 ± 
15 days), which followed the same protocol, apart that saline (saline 0.9%; Fresenius Kabi, 
Bad Homburg, Germany; 1.25 ml × min
–1
) was infused instead of lipid-heparin solution. 
Blood samples were drawn at timed intervals, immediately chilled and centrifuged, and the 
supernatants were stored at -80°C until analysis. Arterialized plasma glucose concentrations 
were measured immediately using the glucose oxidase method on a Dr. Müller Super-GL 
glucose analyzer (Freital, Germany). For the measurements of serum vaspin, blood was 
collected in serum tubes (Bayer, Leverkusen, Germany). 
 
Assays 
Serum vaspin was measured using a commercially available ELISA (Adipogen, Seoul, South 
Korea; intra-assay CV 0.6-2.8%). A relevant interference of lipidemic plasma with the vaspin 
assay was excluded by prior in vitro experiments (data not shown). Measurements of insulin 
in serum and FFA in plasma were performed with Cobas Mira (Roche, Lörrach, Germany). 
HbA1c was measured using HA 8140 (Menarini Diagnostics, Berlin, Germany). HDL and 
 8 
total cholesterol were detected with ABX Pentra 400 (ABX Diagnostics, Montpellier, 
France), while LDL was calculated according to the Friedewald’s formula. 
 
Statistical analysis and calculations 
SPSS 16.0 (Chicago, IL) was used for statistical analysis. If not stated otherwise, data are 
shown as means ± SE. Presence of normal distribution was analysed by the Kolmogorov-
Smirnov test. Not-normally distributed data (i.e. HOMA-IR) were logarithmically 
transformed. In the cross-sectional study, two-way ANOVA was applied to detect combined 
effects (i.e. sex × BMI as a categorical variable) on serum vaspin. Student’s t-test for 
independent samples was used for subgroup analyses if data were normally distributed. 
Otherwise Mann-Whitney U test was applied. The gender distribution within the BMI 
quartiles was compared by a Chi-Square test. Changes of circulating vaspin during lipid vs 
saline clamps were analysed using repeated-measures ANOVA with treatment and time as 
within-subject factors and Huynh–Feldt epsilon correction. Subgroup analyses were 
performed using two-tailed Student’s t-test for paired samples. Linear relationships were 
tested by least square regression analysis. Significance level was defined as P < 0.05. 
 
Results 
 
Cross-sectional study 
From the 120 initially identified subjects 12 had to be excluded because they did not meet all 
of the inclusion criteria. Baseline characteristics of the 108 study subjects are summarized in 
Table 1. The gender distribution within the BMI quartiles was not different (P = 0.75). The 
study population showed a wide variety of age (range: 21.1-72.4 years) and BMI (range: 15.8-
47.8 kg/m
2
). Regarding the 83 individuals with available EHC data, M-value was 4.70  0.33 
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and 4.33  0.32 mg × kg
–1
 × min
–1 
for males and females, respectively, with no significant 
difference between genders (P = 0.40). 
When analysing the entire study group serum vaspin ranged from 0.05 to 3.45 ng/ml, with a 
mean of 0.50  0.06 ng/ml. Surprisingly, we found the highest serum vaspin levels in normal-
weight subjects (lean: 0.58  0.18 ng/ml; normal weight: 0.76  0.14 ng/ml; overweight: 0.29 
 0.81 ng/ml; obese: 0.34  0.05 ng/ml). Further, we observed significantly higher serum 
vaspin levels in women vs men (0.66  0.10 vs 0.29  0.04 ng/ml, P = 0.001). However, 
regression analysis indicated that the variance of serum vaspin within the entire group of 
females was significantly associated with the usage of oral contraceptives (OC) (B = 0.282, P 
= 0.03; R
2
 = 0.30, P < 0.001 for the total model), and this effect remained statistically 
significant after excluding subjects with IGT (OC: B = 0.325, P = 0.03; R
2
 = 0.365, P = 0.001 
for the total model). Additionally, females using OC showed significantly higher serum 
vaspin levels vs females without OC usage (1.17 ± 0.26 vs 0.52 ± 0.09 ng/ml, P = 0.02); 
Figure 1A), and males (1.17 ± 0.26 vs 0.29 ± 0.04 ng/ml, P = 0.01; Figure 1A). 
The main outcome measure of this study was to investigate the potential associations of serum 
vaspin with insulin sensitivity. When analysing all participants using a model with log 
HOMA-IR as the dependent variable and sex, age, BMI, and glucose metabolism (NGM vs 
IGT) as independent variables, a significant association with serum vaspin (B = 0.218, P = 
0.009) became apparent (R
2
 = 0.452, P < 0.001 for the total model). However, after exclusion 
of OC users (n = 13), log HOMA-IR was significantly associated only with BMI (B = 0.649, 
P < 0.001), while we found no correlation with circulating vaspin (B = 0.135, P = 0.10; R
2
 = 
0.416, P < 0.001 for the total model; Table 2, model 1). Additionally, linear regression testing 
in the subgroup of 83 subjects investigated with EHC did not indicate associations of 
circulating vaspin (B = -0.023, P = 0.83) with insulin sensitivity expressed as log M-value, 
whereas, again, a strong correlation with BMI was found (B = -0.479, P < 0.001; R
2
 = 0.174, 
P = 0.001 for the total model; Table 2, model 2). 
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The residual study group (n = 95) was stratified according to BMI quartiles. Males revealed 
increasing serum vaspin with BMI (lean: 0.06  0.01 ng/ml; normal weight: 0.24  0.05 
ng/ml; overweight: 0.34  0.11 ng/ml; obese: 0.31  0.05 ng/ml), while in females peak 
concentrations were observed in normal weight subjects (lean: 0.31  0.11 ng/ml; normal 
weight: 0.86  0.21 ng/ml; overweight: 0.22  0.09 ng/ml; obese: 0.37  0.09 ng/ml. The 
gender difference concerning circulating vaspin was abrogated (P = 0.07; Figure 1A). 
However, a linear regression model adjusted for BMI (B = -0.097, P = 0.34) and age (B = -
0.143, P = 0.16) revealed a significant, although small effect of sex (B = -0.218, P = 0.03; R
2
 
= 0.052, P = 0.04 for the total model), which persisted when IGT individuals were excluded 
(sex: B = -0.304, P = 0.01; R
2
 = 0.124, P = 0.009 for the total model). We further divided the 
residual cross-sectional subjects into groups with BMI < 25 kg/m
2
 vs BMI  25 kg/m
2
. A 
significant sexual dimorphism was found in individuals with a BMI < 25 kg/m
2
 (P = 0.009; 
Figure 1B), while no differences became apparent in overweight and obese subjects (P = 0.91; 
Figure 1B). According to this stratification, two-way ANOVA exposed a significant effect of 
sex (P = 0.04) and sex × BMI (P = 0.03) on circulating vaspin levels. Thus, our results 
support the hypothesis of a gender effect on circulating vaspin in lean and normal weight 
subjects, while the usage of OC could exert further relevant effects on the regulation of serum 
levels. 
When dividing the residual group according to IGT vs NGM (Figure 1C), two-way ANOVA 
exposed no effect of IGT (P = 0.59) or sex × IGT (P = 0.14) on serum vaspin. Also after 
stratification according to BMI, there was neither a significant impact of IGT (P = 0.60 and P 
= 0.09 for BMI < 25 kg/m
2
 vs BMI  25 kg/m
2
, respectively), nor did we find a significant 
interaction of sex and IGT (P = 0.91 and P = 0.80 for BMI < 25 kg/m
2
 vs BMI  25 kg/m
2
, 
respectively). 
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Lipid vs saline intervention study 
We further investigated whether induction of insulin resistance via lipid infusion affects 
circulating vaspin. During both, saline and lipid intervention, plasma glucose levels were 
clamped and thus remained stable at a level of 4.6  0.1 mmol/l without significant 
differences between groups (treatment × group effect: P = 0.13; Figure 2A). Steady state was 
reached at a mean of 137.6  9.0 min. 
As expected following insulin infusion, a significant time × treatment effect concerning serum 
insulin was observed (baseline vs all other time points: P < 0.001 for both, lipid and saline 
infusion, respectively), which was comparable between groups (treatment × group effect: P = 
0.43; Figure 2B). Plasma FFA initially decreased according to insulin infusion during both, 
lipid and saline intervention (time × treatment effect: P < 0.001, respectively; Figure 2C). 
However, plasma FFA over time rose significantly only during the lipid clamps (time × 
treatment effect: P = 0.02; Figure 2C), and the increment in plasma FFA was significant in 
comparison to saline intervention (treatment × group effect: P = 0.001; Figure 2C). 
As expected from our experimental design, peripheral insulin sensitivity significantly 
decreased in lipid-exposed subjects (baseline M-value 6.98  0.76 vs 5.24  0.91 mg × kg
–1
 × 
min
–1
 after lipid challenge; P = 0.008) but not during the saline clamps (baseline M-value 
6.55  0.86 vs 6.75  0.59 mg × kg
–1
 × min
–1
 after saline; P = 0.67). Despite euglycemic 
hyperinsulinemia and insulin resistance with significantly raised plasma free fatty acids 
during lipid intervention, neither a time × treatment effect (P = 0.21, P = 0.37 for saline and 
lipid infusion, respectively) nor a significant difference between lipid and saline EHCs was 
observed concerning serum vaspin levels (treatment × group effect: P = 0.44; Figure 2D). 
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Discussion 
Previous studies suggest a significant association of serum vaspin with insulin resistance, both 
as estimated using HOMA-IR (7,8,9) and when measured using EHCs as the gold standard 
method for the measurement of insulin sensitivity (6). However, although we confirmed an 
association of circulating vaspin with HOMA-IR in the entire study group, this effect was 
abolished after excluding OC users, indicating a strong influence of OC usage on circulating 
vaspin. Consequently, OC users were excluded from further analyses. No association of 
circulating vaspin with M-value derived from EHCs was found, and also lipid-induced insulin 
resistance did not affect serum vaspin. 
In contrast to our findings, a recent investigation reports serum vaspin to correlate negatively 
with the BMI-adjusted GIR in NGM humans, while no association was shown in type 2 
diabetic patients (6). These differences in findings could be partly explained by the varying 
characteristics of the here investigated subjects compared to the participants in the mentioned 
study. More importantly, no adjustment for OC usage was reported in the mentioned study, 
which might have contributed to diverse findings. 
As an additional possibility, the regulation of serum vaspin might have been influenced by 
metabolic control, since a recent study shows a glucose dependent up-regulation of vaspin net 
production and secretion in human omental adipose tissue explants (8). Furthermore, in 
humans a positive association with glycemic control and anti-diabetic treatment was observed 
(7,10). However, within the present study we found neither an association of serum vaspin 
with HbA1c nor we detected a significant impact of IGT on circulating vaspin. 
We found significantly higher circulating vaspin levels in females vs males, which is in 
accordance with some (6,10), but not all previous studies (9,11). The here observed 
association of circulating vaspin with OC usage could provide a potential explanation 
concerning the observed gender differences. This hypothesis is supported by recent data 
showing that treatment of omental adipose tissue from women with polycystic ovary 
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syndrome with different doses of 17 -estradiol exhibits a dose-dependent, albeit insignificant, 
increase in vaspin levels (8). Furthermore, a significant decrease of 17 -estradiol in response 
to metformin therapy, accompanied by a fall in serum vaspin, was reported (8). These 
findings underline the theory that OC might have influenced the variance of serum vaspin in 
our females. Otherwise, it is noteworthy that after exclusion of the OC users we detected an 
influence of gender per se.  
The present study further supports the existence of an interaction between serum vaspin, sex 
and BMI, at least in normal weight and lean subjects, while no such association was detected 
in individuals with a BMI  25 kg/m
2
. Since vaspin is mainly produced by VAT in humans 
(3), we would have expected increasing serum levels with a rising waist circumference and 
BMI. However, circulating vaspin increased with BMI only in males, while in the group of 
females, we paradoxically observed highest serum levels in normal weight subjects. In 
accordance with our findings, a previous study also reported significantly increased serum 
vaspin levels with a rising BMI in males, while in females vaspin peaked in the overweight 
and tended to decrease again in the obese participants (6). This U-shaped relationship between 
body mass and serum vaspin has been recently affirmed in elderly overweight subjects with 
carotid stenosis (11). Therefore, apart from further assessing the potential impact of OC usage 
and sex steroid hormones, investigating potential associations of circulating vaspin with body 
fat distribution could be of interest in future studies.  
Limitations of the present study need to be addressed. We may have missed small differences 
between groups both in the cross-sectional study and in the lipid-saline sub-study, due to the 
relatively low number of participants investigated. In addition, a longer duration of the 
intervention may have further elucidated potentially present effects, although the lack of an 
association of circulating vaspin with insulin resistance in the cross-sectional study suggests 
the absence of a major interference. 
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In conclusion, we found no major association of serum vaspin with insulin sensitivity, at least 
in the here investigated cohort of non-diabetic humans with widely varying BMI. Our results 
further support the hypothesis of a sexual dimorphism concerning serum vaspin, but they also 
propose that interfering factors including the usage of OC should be regarded as potential 
confounders in future studies.  
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Table 1 Baseline characteristics of the cross-sectional study population. 
 
 
 
females 
 
males 
 
P 
N 62 46 - 
Age (years) 46.6 ± 2.0 50.4 ± 2.2 0.21 
BMI (kg/m
2
) 27.7 ± 1.2 29.3 ± 0.9 0.30  
Waist circumference (cm) 87.0 ± 2.8 99.3 ± 2.3 0.001 
Fasting plasma glucose (mmol/l) 4.92 ± 0.07 5.12 ± 0.07 0.08 
120 min OGTT-plasma glucose (mmol/l) 7.36 ± 0.18 6.80 ± 0.24 0.04 
HbA1c (%) 5.20 ± 0.06 5.23 ± 0.05 0.73 
HOMA-IR 1.81 ± 0.21 1.92 ± 0.22 0.73 
LDL (mmol/l) 3.7 ± 0.48 3.41 ± 0.15 0.63 
HDL (mmol/l) 1.54 ± 0.05 1.39 ± 0.06 0.06 
Plasma triglycerides (mmol/l) 1.12 ± 0.06 1.34 ± 0.09 0.04 
Plasma FFA (mmol/l) 0.59 ± 0.03 0.53 ± 0.04 0.17 
SBP (mm Hg) 117 ± 2 134 ± 3 < 0.001 
DBP (mm Hg) 74 ± 1 81 ± 2 0.007 
IGT (n) 21 9 - 
Antihypertensive medication (n) 11 13 - 
Statin (n) 1 0 - 
Contraceptives (n) 13 0 - 
Antidepressive medication (n) 2 2 - 
Others (antiobstructive inhalator, H1-
Blocker, PPI) (n) 
3 2 - 
 
Means ± SEM or absolute number of subjects under medical treatment is shown. 
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BMI, body mass index; DBP, diastolic blood pressure; FFA, free fatty acids; HDL, high 
density lipoprotein; HOMA-IR, homeostasis-model-assessment for insulin resistance; IGT, 
impaired glucose tolerance; LDL, low density lipoprotein; OGTT, oral glucose tolerance test; 
PPI, proton pump inhibitors; SBP, systolic blood pressure. 
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Table 2 Multivariate analysis of parameters associated with HOMA-IR and M-value in the 
cross-sectional study. 
 
Independent variables 
 
Beta coefficient 
 
P value 
 
Model 1: Study group with females using OC excluded 
(n = 95; R
2
 = 0.416, P < 0.001)  
 
log HOMA-IR 
BMI   0.649      < 0.001 
Sex 0.129 0.11 
Age -0.124 0.13 
Serum vaspin 0.135 0.10 
 
Model 2: EHC subgroup with females using OC 
excluded (n = 76; R
2
 = 0.174, P = 0.001) 
 
log M-value 
BMI -0.479     < 0.001 
Sex 0.151 0.18 
Age -0.001 0.99 
Serum vaspin -0.023 0.84 
 
BMI, body mass index; EHC, euglycemic hyperinsulinemic clamp; HOMA-IR, homeostasis-
model-assessment for insulin resistance; OC, oral contraceptives. 
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Figure legends 
 
Figure 1 Gender related distribution of vaspin serum concentrations in the cross-sectional 
study (n = 108). Data are means  SEM; , female subjects; , male subjects. 
A: Circulating vaspin in females using OC (n = 13; left black bar) vs females without OC 
usage (n = 49; right black bar, P < 0.01) and vs male subjects (n = 46; P = 0.027). Females 
without OC usage vs males: P = 0.07. 
B: Vaspin serum concentrations of the study group after the exclusion of OC users stratified 
according to BMI and gender (n = 95). BMI < 25 kg/m
2
, females vs males (P = 0.009; left 
bars) and BMI  25 kg/m
2
, females vs males (P = 0.90; right bars). 
C: Circulating vaspin of NGM (n = 78, males n = 37; P = 0.027) and IGT female vs male 
subjects (n = 27, males n = 9; P = 0.72). 
 
Figure 2 Intervention study (n = 10). 
EHC with 300 min lipid vs saline infusion (n = 10). Peripheral concentrations of plasma 
glucose (A), serum insulin (B) and plasma free fatty acids (C) during intervention. Data of 
serum vaspin (D) are expressed as fold difference in lipid vs saline exposed subjects relative 
to the overnight fasted state. 
Data are means  SEM for n = 10 normal glucose tolerant subjects. 
(B) time × treatment effect for insulin: Baseline vs all other time points: P < 0.001 for both 
lipid and saline infusion, respectively. 
(C) time × treatment effect for FFA due to insulin infusion, P < 0.001. Treatment × group 
effect lipid vs saline infusion, P = 0.001. Single time points: * P < 0.05, ** P < 0.01. 
(D) time × treatment effect for serum vaspin, P = 0.21. Treatment x group effect lipid vs 
saline infusion, P = 0.44. 
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